Percutaneous coronary intervention causes increase of serum cystatin C concentration even in the patients with a low risk of contrast-induced nephropathy

Cardiovascular Intervention and Therapeutics

Volumn 27, Issue 3, 2012, Pages 168-173

  Tanaga, Kosei ^a   Tarao, Kentarou ^a   Nakamura, Yoshitake ^a   Inoue, Toshihisa ^a   Jo, Kigen ^a   Ishikawa, Takayasu ^a   Miyazaki, Akira ^a  

^a CHIBA CARDIOVASCULAR CENTER   (Japan)

Author keywords

Contrast induced nephropathy; Cystatin C; Percutaneous coronary intervention

Indexed keywords

CONTRAST MEDIUM; CREATININE; CYSTATIN C;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; CARDIOGENIC SHOCK; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EMERGENCY TREATMENT; FEMALE; HUMAN; INTRAAORTIC BALLOON PUMP; KIDNEY FAILURE; KIDNEY FUNCTION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84874215104     PISSN: 18684300     EISSN: 18684297     Source Type: Journal    
DOI: 10.1007/s12928-012-0106-3     Document Type: Article

References (19)

1. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006; 113: 1799-806.
2. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51: 1419-28.
3. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004; 44: 1393-9.
4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002; 105: 2259-64.
5. Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004; 94: 300-5.
6. Kawamura Y, Morino Y, Nagaoka M, Matsukage T, Masuda N, Ikari Y. Impact of chronic kidney disease on clinical and angiographic results following implantation of sirolimus-eluting coronary stents. Cardiovasc Interv Ther. 2011; 26: 18-25.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Eng J Med. 2004; 351: 1296-305.
8. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992; 38: 1933-53.
9. Abrahamson M, Olafsson I, Palsdottir A, Ulvsbäck M, Lundwall A, Jensson O, et al. Structure and expression of the human cystatin C gene. Biochem J. 1990; 268(2): 287-94.
10. Laterza OF, Price CP, Scott MG, Laterza OF, Prince CP, Scott MG, Cystatin MG. An improver estimator of glomerular filtration rate? Clin Chem. 2002; 48: 2297-8.
11. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995; 47: 312-8.
12. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002; 40: 221-6.
13. 2-microglobulin, and urinary liver-type fatty acid-binding protein on the development of contrast-induced nephropathy. Cardiovasc Interv Ther. 2010; 25: 85-90.
14. Freeman RV, O'Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002; 90: 1068-73.
15. Tanaka M, Matsuo K, Enomoto M, Mizuno K. A sol particle homogeneous immunoassay for measuring serum cystatin C. Clin Biochem. 2004; 37: 27-35.
16. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007; 115: 173-9.
17. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008; 359: 677-87.
18. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002; 162: 329-36.
19. Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl. 2006; 100: S51-3.